NCT00791323

Efficacy of Ketorolac 0.4% in Prostaglandin Suppression

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A pilot study to evaluate the extent of PGE2 inhibition (mean aqueous values) by Ketorolac 0.04% following peripheral iridotomy

Conditions

• Inflammation

Interventions

Type	Name	Description
DRUG	Ketorolac 0.4%	One drop 4 times a day in the pre-operative eye beginning day 0 for 4 days
DRUG	Lubricating Eye Drop	One drop 4 times a day in the operative eye beginning one day prior to the peripheral iridotomy and continuing until the day of IOL implantation

Timeline

• Start date: 2008-11-01
• Primary completion: 2009-08-01
• Completion: 2009-08-01
• First posted: 2008-11-14
• Last updated: 2011-09-23
• Results posted: 2011-09-23

Locations

1 site across 1 country: United States